Effects of quercetin on the sleep-wake cycle in rats: Involvement of gamma-aminobutyric acid receptor type A in regulation of rapid eye movement sleep

Brain Research

Volumn 1330, Issue , 2010, Pages 83-88

  Kambe, Daiji ^a,b   Kotani, Makiko ^a   Yoshimoto, Makoto ^a   Kaku, Shinsuke ^a   Chaki, Shigeyuki ^a   Honda, Kazuki ^b  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Gamma aminobutyric acid receptor; Quercetin; Sleep; Type a

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BICUCULLINE; QUERCETIN; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; CENTRAL NERVOUS SYSTEM AGENTS;

ANIMAL EXPERIMENT; ARTICLE; DARKNESS; DRUG EFFECT; ELECTROENCEPHALOGRAM; ELECTROMYOGRAM; MALE; NONHUMAN; NONREM SLEEP; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; REM SLEEP; SLEEP WAKING CYCLE; ANIMAL; CIRCADIAN RHYTHM; DRUG ANTAGONISM; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PHOTOPERIODICITY; PHYSIOLOGY; SLEEP; SPRAGUE DAWLEY RAT; WAKEFULNESS;

RATTUS;

ANIMALS; BICUCULLINE; CENTRAL NERVOUS SYSTEM AGENTS; CIRCADIAN RHYTHM; DARKNESS; GABA ANTAGONISTS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; MALE; PHOTOPERIOD; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A; SLEEP; SLEEP, REM; WAKEFULNESS;

EID: 77955896119     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.03.033     Document Type: Article

References (43)

1. Agullo, G., Gamet-Payrastre, L., Manenti, S., Viala, C., Rémésy, C., Chap, H., Payrastre, B., 1997. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem. Pharmacol. 53, 1649-1657.
2. Akanmu, M.A., Honda, K., 2005. Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats. Brain Res. 1048, 138-145. (Pubitemid 40800268)
3. Aston-Jones, G., Bloom, F.E., 1981. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J. Neurosci. 1, 876-886. (Pubitemid 11025876)
4. Bjorvatn, B., Fagerland, S., Eid, T., Ursin, R., 1997. Sleep/waking effects of a selective 5-HT1A receptor agonist given systemically as well as perfused in the dorsal raphe nucleus in rats. Brain Res. 770, 81-88. (Pubitemid 27468054)
5. Boissard, R., Gervasoni, D., Schmidt, M.H., Barbagli, B., Fort, P., Luppi, P.H., 2002. The rat ponto-medullary network responsible for paradoxical sleep onset and maintenance: a combined microinjection and functional neuroanatomical study. Eur. J. Neurosci. 16, 1959-1973.
6. Burkard, W.P., Bonetti, E.P., Da Prada, M., Martin, J.R., Pole, P., Schaffner, R., Scherschlicht, R., Hefti, F., Müller, R.K., Wyss, P.C., 1989. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248, 391-399.
7. Caille, D., Bergis, O.E., Fankhauser, C., Gardes, A., Adam, R., Charieras, T., Grasset, A., Rovei, V., Jarreau, F.X., 1996. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J. Pharmacol. Exp. Ther. 277, 265-277.
8. Chen, X., Yin, O.Q., Zuo, Z., Chow, M.S., 2005. Pharmacokinetics and modeling of quercetin and metabolites. Pharm. Res. 22, 892-901.
9. Chimenti, F., Cottiglia, F., Bonsignore, L., Casu, L., Casu, M., Floris, C., Secci, D., Bolasco, A., Chimenti, P., Granese, A., Befani, O., Turini, P., Alcaro, S., Ortuso, F., Trombetta, C., Loizzo, A., Guarino, I., 2006. Quercetin as the active principle of Hypericum hircinum exerts a selective inhibitory activity against MAO-A: extraction, biological analysis, and computational study. J. Nat. Prod. 69, 945-949.
10. Cirelli, C., Tononi, C., 2000. Gene expression in the brain across the sleep-waking cycle. Brain Res. 885, 303-321.
11. Conti, B., Maier, R., Barr, A.M., Morale, M.C., Lu, X., Sanna, P.P., Bilbe, C., Hoyer, D., Bartfai, T., 2007. Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol. Psychiatry 12, 167-189. (Pubitemid 46160982)
12. Filho, A.W., Filho, V.C., Olinger, L., de Souza, M.M., 2008. Quercetin: further investigation of its antinociceptive properties and mechanisms of action. Arch. Pharm. Res. 31, 713-721.
13. Formica, J.V., Regelson, W., 1995. Review of the biology of Quercetin and related bioflavonoids. Food Chem. Toxicol. 33, 1061-1080.
14. Han, X.H., Hong, S.S., Hwang, J.S., Lee, M.K., Hwang, B.Y., Ro, J.S., 2007. Monoamine oxidase inhibitory components from Cayratia japonica. Arch. Pharm. Res. 30, 13-17.
15. Honda, K., Komoda, Y., Nishida, S., Nagasaki, H., Higashi, A., Uchizono, K., Inoué, S., 1983. Uridine as an active component of sleep-promoting substance: its effects on nocturnal sleep in rats. Neurosci. Res. 1, 243-252.
16. Honda, K., Komoda, Y., Inoué, S., 1994. Oxidized glutathione regulates physiological sleep in unrestrained rats. Brain Res. 636, 253-258. (Pubitemid 24044642)
17. Ikeda, M., Ikeda-Sagara, M., Okada, T., Clement, P., Urade, Y., Nagai, T., Sugiyama, T., Yoshioka, T., Honda, K., Inoué, S., 2005. Brain oxidation is an initial process in sleep induction. Neuroscience 130, 1029-1040. (Pubitemid 40094633)
18. Jhaveri, K.A., Trammell, R.A., Toth, L.A., 2007. Effect of environmental temperature on sleep, locomotor activity, core body temperature and immune responses of C57BL/6J mice. Brain Behav. Immun. 21, 975-987.
19. Kaur, R., Singh, D., Chopra, K., 2005. Participation of alpha2 receptors in the antinociceptive activity of quercetin. J. Med. Food 8, 529-532. (Pubitemid 43121908)
20. Kellenberger, S., Malherbe, P., Sigel, E., 1992. Function of the alpha 1 beta 2 gamma 2S gamma-aminobutyric acid type A receptor is modulated by protein kinase C via multiple phosphorylation Sites. J. Biol. Chem. 267, 25660-25663.
21. Komoda, Y., Honda, K., Inoue, S., 1990. SPS-B, a physiological sleep regulator, from the brainstems of sleep-deprived rats, identified as oxidized glutathione. Chem. Pharm. Bull. (Tokyo) 38, 2057-2059.
22. Krueger, J.M., Majde, J.A., 2003. Humoral links between sleep and the immune system: research issues. Ann. N. Y. Acad. Sci. 992, 9-20.
23. Lamson, D.W., Brignall, M.S., 2000. Antioxidants and cancer, part 3: quercetin. Altern. Med. Rev. 5, 196-208.
24. Liu, J., Yu, H., Ning, X., 2006. Effect of quercetin on chronic enhancement of spatial learning and memory of mice. Sci. China C Life Sci. 49, 583-590.
25. Lu, J., Sherman, D., Devor, M., Saper, C.B., 2006. A putative flip-flop switch for control of REM sleep. Nature 441, 589-594. (Pubitemid 43927285)
26. Mallick, B.N., Singh, S., Pal, D., 2005. Role of alpha and beta adrenoceptors in locus coeruleus stimulation-induced reduction in rapid eye movement sleep in freely moving rats. Behav. Brain Res. 158, 9-21.
27. McCarley, R.W., 2007. Neurobiology of REM and NREM sleep. Sleep Med. 8, 302-330.
28. McGinty, D.J., Harper, R.M., 1976. Dorsal raphe neurons: depression of firing during sleep in cats. Brain Res. 101, 569-575.
29. Middleton Jr., E., Kandaswami, C., Theoharides, T.C., 2000. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 52, 673-751.
30. Murota, K., Terao, J., 2003. Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch. Biochem. Biophys. 417, 12-17.
31. Naidu, P.S., Singh, A., Kulkarni, S.K., 2003. D2-dopamine receptor and alpha2-adrenoreceptor-mediated analgesic response of quercetin. Indian J. Exp. Biol. 41, 1400-1404.
32. Nishimuta, H., Ohtani, H., Tsujimoto, M., Ogura, K., Hiratsuka, A., Sawada, Y., 2007. Inhibitory effects of various beverages on human recombinant sulfotransferase isoforms SULT1A1 and SULT1A3. Biopharm. Drug Dispos. 28, 491-500.
33. Pasqualini, J.R., 2009. Estrogen sulfotransferases in breast and endometrial cancers. Ann. N. Y. Acad. Sci. 1155, 88-98.
34. Paxinos, G., Watson, C., 1998. The Rat Brain in Stereotaxic Coordinates, 4th ed. Elsevier/Academic Press, New York.
35. Perez-Vizcaino, F., Duarte, J., Jimenez, R., Santos-Buelga, C., Osuna, A., 2009. Antihypertensive effects of the flavonoid quercetin. Pharmacol. Rep. 61, 67-75.
36. Picq, M., Cheav, S.L., Prigent, A.F., 1991. Effect of two flavonoid compounds on central nervous system. Analgesic activity. Life Sci. 49, 1979-1988.
37. Schrag, M.L., Cui, D., Rushmore, T.H., Shou, M., Ma, B., Rodrigues, A.D., 2004. Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol. Drug Metab. Dispos. 32, 1299-1303.
38. Song, M., Messing, R.O., 2005. Protein kinase C regulation of GABAA receptors. Cell. Mol. Life Sci. 62, 119-127.
39. Spencer, J.P., 2008. Flavonoids: modulators of brain function? Br. J. Nutr. 99, ES60-ES77.
40. Speroni, E., Minghetti, A., 1988. Neuropharmacological activity of extracts from Passiflora incamata. Planta Med. 54, 488-491. (Pubitemid 19007988)
41. Walle, T., Eaton, E.A., Walle, U.K., 1995. Quercetin, a potent and specific inhibitor of the human P-form phenosulfotransferase. Biochem. Pharmacol. 50, 731-734.
42. Williams, R.J., Spencer, J.P., Rice-Evans, C., 2004. Flavonoids: antioxidants or signalling molecules? Free Radic. Biol. Med. 36, 838-849.
43. Youdim, K.A., Qaiser, M.Z., Begley, D.J., Rice-Evans, C.A., Abbott, N.J., 2004. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic. Biol. Med. 36, 592-604.